IP-10 Promotes Latent HIV Infection in Resting Memory CD4+ T Cells via LIMK-Cofilin Pathway

A major barrier to HIV eradication is the persistence of viral reservoirs. Resting CD4 + T cells are thought to be one of the major viral reservoirs, However, the underlying mechanism regulating HIV infection and the establishment of viral reservoir in T cells remain poorly understood. We have inves...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 12; p. 656663
Main Authors Wang, Zhuo, Yin, Xiaowan, Ma, Meichen, Ge, Hongchi, Lang, Bin, Sun, Hong, He, Sijia, Fu, Yajing, Sun, Yu, Yu, Xiaowen, Zhang, Zining, Cui, Hualu, Han, Xiaoxu, Xu, Junjie, Ding, Haibo, Chu, Zhenxing, Shang, Hong, Wu, Yuntao, Jiang, Yongjun
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 10.08.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:A major barrier to HIV eradication is the persistence of viral reservoirs. Resting CD4 + T cells are thought to be one of the major viral reservoirs, However, the underlying mechanism regulating HIV infection and the establishment of viral reservoir in T cells remain poorly understood. We have investigated the role of IP-10 in the establishment of HIV reservoirs in CD4 + T cells, and found that in HIV-infected individuals, plasma IP-10 was elevated, and positively correlated with HIV viral load and viral reservoir size. In addition, we found that binding of IP-10 to CXCR3 enhanced HIV latent infection of resting CD4 + T cells in vitro. Mechanistically, IP-10 stimulation promoted cofilin activity and actin dynamics, facilitating HIV entry and DNA integration. Moreover, treatment of resting CD4 + T cells with a LIM kinase inhibitor R10015 blocked cofilin phosphorylation and abrogated IP-10-mediated enhancement of HIV latent infection. These results suggest that IP-10 is a critical factor involved in HIV latent infection, and that therapeutic targeting of IP-10 may be a potential strategy for inhibiting HIV latent infection.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Arik Cooper, National Institutes of Health (NIH), United States; Jennifer M. Zerbato, Peter Doherty Institute for Infection and Immunity, Australia
These authors have contributed equally to this work
This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology
Edited by: Constantinos Petrovas, Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.656663